drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Intravenous T-cell–engaging bispecific antibody that binds CD20 on malignant B cells and CD3 on T cells to activate TCR/CD3 signaling and mediate T-cell cytotoxicity and cytokine release, depleting CD20+ B cells.
nci_thesaurus_concept_id
C200546
nci_thesaurus_definition
A bispecific antibody and T-cell engager (TCE) targeting both the tumor-associated antigen (TAA) CD20 and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20/anti-CD3 bispecific antibody MBS303 binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. MBS303, composed of a 2:1 bispecific antibody structure, binds to CD20 with two arms and CD3 molecule with one arm to increase affinity with tumor cells and decrease the off-target toxicity of T-cells.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Intravenous 2:1 anti-CD20 × anti-CD3 bispecific antibody that bridges T cells to CD20+ B cells, activating TCR/CD3 signaling to trigger T‑cell cytotoxicity and cytokine release, leading to depletion of malignant CD20-expressing B cells; bivalent CD20 and monovalent CD3 binding enhances tumor targeting and may reduce off-target T‑cell activation.
drug_name
MBS303
nct_id_drug_ref
NCT05806099